恩瑞格国内去哪里买呢？

Maybe many people don’t know much about thalassemia, which is a group of hereditary hemolytic anemia diseases. In recent years, with the increase in incidence, it has gradually entered everyone's field of vision. Currently the best way to treat this disease is through medication. Among them is one of our most effective drugs. Enriga is currently the only oral iron chelator developed by Novartis. It was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions. In December 2012, Enrig was approved by the European Commission for the treatment of chronic iron overload in patients aged 10 years and above with non-transfusion-dependent thalassemia (NTDT) syndrome who require chelation therapy due to contraindications or insufficiency of deferoxamine mesylate therapy. On January 23, 2013, the FDA approved the new indication of Enriga for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) aged 10 years and above. 

The common starting dose is 20 mg/(kg·d). If there is a large amount of blood transfusion and the iron increase is >0.5 mg/(kg·d) or the iron load before treatment is high, the recommended dose is 30 mg/(kg·d). If the iron increase is <0.3 mg/kg, 10-15 mg/kg/d is enough to control the disease. Administer on an empty stomach 30 minutes before meals and should be completely dissolved in water or apple or orange juice. Lower doses of Enrego [5-10 mg/(kg·d)] can only be used in young patients with mild iron overload and few blood transfusions, or in elderly patients who have not received satisfactory results from chelation therapy in the past; patients using deferasole 20 and 30 mg/(kg·d) need to carefully monitor body iron reserves, because body iron levels may continue to rise in 50% and 10% of patients. In addition, the frequency of blood transfusion can also affect the effect of Enrig in controlling liver concentration. When the iron intake is greater than 0.5mg/(kg·d), only 47% of patients who receive the same dose of Enrig have a reduction in liver concentration. 

To put it bluntly, if a patient wants to take Enrig, where can he buy Enrig in China? Since Enrego has been approved for sale in my country, patients can purchase Enrego at large domestic hospitals or pharmacies with a prescription. The only drawback is that the price is relatively high. If the patient chooses India, which is extremely cost-effective, in addition to going to India in person, he can also obtain it through domestic professional overseas medical service institutions.